3.10
View the full transcript and gain access to JoVE Core videos
Q1: How do drugs distribute into tissues after entering the bloodstream?
After entering systemic circulation, drugs distribute into the interstitial fluid and intracellular fluid of various tissue cells. Drugs bind to different cellular components within tissues, which may lead to drug accumulation in specific areas. This binding process facilitates the movement of drugs from the blood into tissue compartments, allowing drugs to exert their therapeutic effects at target sites.
Q2: What role do tissue-bound drugs play in prolonging drug action?
Drugs bound to tissue components serve as reservoirs that slowly release free drug back into the system, prolonging the drug's overall action. This reservoir effect allows for sustained therapeutic activity even after drug administration ceases. However, this accumulation can also result in local toxicity if drugs concentrate excessively in sensitive tissues.
Q3: Why do lipophilic drugs accumulate in body fat?
Lipophilic drugs bind to body fat because fat tissue has high affinity for fat-soluble compounds. Since fat is a poorly perfused tissue with limited blood flow, it functions as a stable drug reservoir for these drugs. This characteristic allows lipophilic drugs to be stored long-term in adipose tissue and released gradually into circulation.
Q4: How can drug accumulation cause nephrotoxic effects?
Acrolein, a metabolic byproduct of cyclophosphamide, binds to renal tissues and accumulates within renal cells, causing nephrotoxic effects. When drugs concentrate in kidney tissue, they can damage renal cells and impair kidney function. This example demonstrates how drug accumulation in specific tissues can lead to organ-specific toxicity despite therapeutic benefits elsewhere.
Q5: How does alendronate therapy utilize bone as a drug storage site?
In osteoporosis treatment, alendronate's phosphonate component binds to hydroxyapatite crystals in the mineralized bone matrix and resists degradation, preserving bone structure. Bones function as drug storage sites where alendronate accumulates and acts locally to prevent bone loss. This targeted accumulation allows the drug to exert prolonged therapeutic effects on bone tissue.
Q6: What adverse effects can result from toxic metal accumulation in bones?
Bones can serve as reservoirs for toxic metals, which may be released slowly into the bloodstream, leading to various adverse effects. This slow release mechanism prolongs systemic exposure to toxins even after external exposure ceases. The gradual mobilization of accumulated metals from bone can cause chronic toxicity affecting multiple organ systems.
Q7: What is the relationship between tissue binding and drug distribution volume?
Tissue binding directly influences drug distribution volume by determining how extensively drugs partition into tissues versus remaining in plasma. Drugs with high tissue binding accumulate in various compartments, increasing their apparent volume of distribution. Understanding tissue binding patterns helps predict drug distribution and is essential for calculating appropriate dosing regimens.